J. Goldman & CO LP Viking Therapeutics, Inc. Put Options Transaction History
J. Goldman & CO LP
- $3.27 Billion
- Q2 2024
Put Options
1 transactions
Others Institutions Holding VKTX
# of Institutions
484Shares Held
66.7MCall Options Held
5.94MPut Options Held
3.01M-
Vanguard Group Inc Valley Forge, PA10.2MShares$616 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$365 Million0.01% of portfolio
-
State Street Corp Boston, MA5.12MShares$310 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.12MShares$128 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA1.86MShares$113 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $4.65B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...